Upgrade to SI Premium - Free Trial

Viking Therapeutics (VKTX)

34.87 +0.89 (2.62%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/28/26)

Latest Headlines

Viking Therapeutics (VKTX) PT Lowered to $65 at JPMorgan August 11, 2026 8:49 AM - StreetInsider Form 4 Viking Therapeutics, For: Aug 01 Filed by: Kelly-Gemmell Dorothy Elizabeth August 7, 2026 4:35 PM - SEC Filing Form 3 Viking Therapeutics, For: Aug 01 Filed by: Kelly-Gemmell Dorothy Elizabeth August 7, 2026 4:34 PM - SEC Filing Viking Therapeutic (VKTX) PT Raised to $114 at Canaccord July 30, 2026 7:21 AM - StreetInsider Viking Therapeutics (VKTX) files mixed shelf July 30, 2026 6:08 AM - StreetInsider Form S-3ASR Viking Therapeutics, July 30, 2026 6:04 AM - SEC Filing Form 4 Viking Therapeutics, For: Jul 28 Filed by: Lian Brian July 29, 2026 8:07 PM - SEC Filing Form 4 Viking Therapeutics, For: Jul 28 Filed by: ZANTE GREG July 29, 2026 8:07 PM - SEC Filing Form 4 Viking Therapeutics, For: Jul 28 Filed by: Mancini Marianna July 29, 2026 8:06 PM - SEC Filing Form 10-Q Viking Therapeutics, For: Jun 30 July 29, 2026 5:16 PM - SEC Filing Viking Therapeutics (VKTX) Tops Q2 EPS by 13c July 29, 2026 4:30 PM - StreetInsider Form 144 Viking Therapeutics, Filed by: Lian Brian July 29, 2026 4:19 PM - SEC Filing Form 8-K Viking Therapeutics, For: Jul 29 July 29, 2026 4:06 PM - SEC Filing Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update July 29, 2026 4:05 PM - PR NewsWire Form 144 Viking Therapeutics, Filed by: ZANTE GREG July 29, 2026 4:05 PM - SEC Filing Form 144 Viking Therapeutics, Filed by: Mancini Marianna July 29, 2026 4:03 PM - SEC Filing Viking Therapeutics adds Dorothy Gemmell to its board of directors July 23, 2026 7:05 AM - StreetInsider Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors July 23, 2026 7:05 AM - PR NewsWire Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 July 22, 2026 4:05 PM - PR NewsWire Piper Sandler Reiterates Overweight Rating on Viking Therapeutic (VKTX) July 7, 2026 7:52 AM - StreetInsider Viking Therapeutic (VKTX) Reiterated at Overweight by Cantor Fitzgerald July 1, 2026 7:03 AM - StreetInsider Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019 June 24, 2026 7:05 AM - StreetInsider Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults June 24, 2026 7:05 AM - PR NewsWire Viking Therapeutics names Hubert Chen as chief medical officer June 11, 2026 7:05 AM - StreetInsider Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer June 11, 2026 7:05 AM - PR NewsWire Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows June 9, 2026 2:31 PM - StreetInsider Full Article List